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Synopsis
Hydrogen magnetic resonance spectroscopy (1H-MRS) is a technically challenging modality. It has the potential to provide specific
metabolic information that could guide clinical decision making. In this study we assess feasibility of performing 1H MRS in patients with
head and neck squamous cell carcinoma (HNSCC) prior to treatment and explore its correlation with post-treatment outcomes.
Introduction
Head and neck squamous cell carcinoma (HNSCC) remains one of the most debilitating and disfiguring types of cancer. Despite advances and
durable treatment responses in other cancers, recurrent disease has been reported in 50% of patients with HNSCC1. Therefore, the ability to predict
treatment outcome could be improved if reliable imaging biomarkers could be developed. This would help clinicians stratify patients based on the
aggressiveness of the disease. In this study, we assessed tissue metabolites in correlation to treatment outcomes using hydrogen magnetic
resonance spectroscopy (1H-MRS) 2,3
Methods
Following institutional approval and consent, 35 patients with HNSCC were recruited for 1H-MRS prior to treatment and followed-up following
treatment over a 2 year period.
Prior to treatment, all patients were scanned on a 1.5T MR scanner (MAGNETOM Avanto, Siemens AG, Erlargen, Germany) using the carotid coils in
the supine position. Anatomical MR imaging across the 3 orthogonal planes was acquired for the 1H-MRS localisation. Manual shimming was
performed to ensure acceptable spectral quality and a 15 x 15 x 15 mm3 spectroscopic volume of interest (VOI) was placed over the diseased node
(Figure 1). A point resolved spectroscopy technique was used with the following parameters: TE=144ms, TR=2000ms, bandwidth=1000Hz, 1024
points acquiring 56 measurements of 4 averages. When the manual shimming was not possible or the spectral quality was too poor, the spectra were
excluded. Post-processing analysis was performed using jMRUI package (Figure 2). The water peaks were used for the phase and frequency
corrections, and a Hankel-Lanczos singular value decomposition (HLSVD) filter was utilised to remove water (4.7ppm), methyl (0.9ppm) and
methylene (1.3ppm). The data were apodised with a 5Hz Gaussian filter and AMARES fitting method was used to estimate the choline/creatine
(Cho/Cr) peaks.
Two medical physicists independently scored the quality of the 1H-MR spectra with a scoring range from 1 to 5. The sum of the scores was
calculated and a cut oﬀ value of >6 was agreed to indicate minimum quality of spectra to be analysed. Cho/Cr ratios were derived for all analysable
datasets.
Patients were classified into those with local complete response (CR, n=20) or nodal
recurrent/residual disease (RD, n=15) depending on the presence or absence of any local
disease relapse based on multi-disciplinary consensus review informed by clinical, imaging
and histopathological follow-up. Cho/Cr ratios were compared using an unpaired student t-
test between the two groups analysable datasets.
Results
7/35 patients had spectra identified with score of 7 or greater (Figure 3). This was our spectral quality threshold score. Following exclusion of the
spectra with lower quality scores of less than 7, the Cho/Cr peak ratios were statistically compared between the two patient groups (number of CR
patients = 4 and number of RD patients=3). The mean Cho/Cr ratio of patients within the CR group was (2.0) and was lower than patients within the
RD group (4.22) . The comparison of the two groups was statistically significant with a p value of 0.02.
Discussion
Our results demonstrate feasibility of using Cho/Cr metabolite ratio as a marker of treatment response. However, we found the technique challenging
to apply in the head and neck region – likely related to shimming tolerances of clinical systems 5. Having a minimum of two or more experienced






Page 2 of 3https://submissions.mirasmart.com/ISMRM2018/ViewSubmission.aspx?sbmID=779
independent scorers allowed us to apply quality control and with the limited number of datasets that passed the quality control threshold we were
able to demonstrate significant diﬀerences in Cho/Cr ratios between the two patient groups.
Conclusion
This study demonstrates the potential clinical value of 1H-MRS as a imaging biomarker as pre-treatment indicator of 2 year treatment outcome in
HNSCC. The challenge of obtaining spectra of suﬃcient quality is highlighted by the high rejection rate during our quality control process. Strategies
(preparation/acquisition/post-processing) to improve data quality in the head and neck region will need development before clinical application of
Cho/Cr ratios within this patient cohort can be prospectively tested.
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Figures
Image showing a patient’s left enlarged cervical node (denoted with red arrow), undertaken hydrogen magnetic resonance spectroscopy
measurement.
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A typical example of patient’s hydrogen magnetic resonance (1H-MR) spectra (patient’s code: HN09) showing the original spectrum, the estimated
individual components and the estimated spectrum. This spectrum has been analysed, curated and scored.
Choline/creatine ratio summary obtained by two medical physicists of the 1H-MR spectra identified with score of 7 or greater
